Objectives: There are controversies regarding the association of cefepime therapy with increased mortality among patients with infections caused by Gram-negative bacteria (GNB). We evaluated the effect of cefepime on the mortality of patients with GNB bloodstream infections (BSIs).
Introduction
Cefepime is a fourth-generation cephalosporin with broadspectrum antibacterial activity, which has been widely used since its approval for clinical use in 1997. 1 It has been used for the treatment of many severe infectious conditions, including pneumonia, complicated urinary tract infections and complicated intra-abdominal infections, and as empirical therapy for febrile neutropenia. 1 In 2007, a meta-analysis of randomized clinical trials found that therapy with cefepime was associated with a 26% increase in mortality in relation to other antibiotics used in comparator arms. 2 A subsequent meta-analysis including unpublished clinical trials has not confirmed such results. 3 Although both meta-analyses have their limitations and have been partially criticized, 4, 5 it seems that at least a trend to increased mortality does exist in patients receiving cefepime therapy. 6 Although it was not their aim, recent observational studies have provided some insights regarding possible causes for the finding of increased mortality with cefepime. It has been shown that mortality rates are significantly higher in patients with infections caused by Gram-negative bacteria (GNB) with MICs .1 mg/ L, particularly 8 mg/L, which is within the susceptibility breakpoint according to CLSI. 7, 8 Indeed, there is a strong pharmacokinetic/ pharmacodynamic (PK/PD) rationale that supports such findings. The probability of target attainment (PTA), usually free drug concentrations above the MIC (fT .MIC ) for at least 60% -70% of the dosing interval, is very low using most commonly prescribed dosage regimens (1 g every 12 h or every 8 h and 2 g every 12 h) if the organism has an MIC ¼ 8 mg/L, but PTA is frequently .80% with a dosage of 2 g every 8 h. 9, 10 The PTA is even higher if this high-dose regimen is administered over an extended infusion. 11, 12 However, with the exception of one observational study that showed lower mortality rates in patients receiving high-dose, 3 h cefepime infusions compared with 30 min infusions in patients with severe infections caused by Pseudomonas aeruginosa, with MIC 50 and MIC 90 values of 4 and 8 mg/L, respectively, 12 none of the studies that has assessed the effect of MIC has evaluated dosage regimen as a covariate potentially associated with the outcome. Actually, dosage regimens were predominantly or exclusively the 'usual' ones, i.e. 1 g every 12 h or every 8 h and 2 g every 12 h. 7, 8 In this study, we compared a high-dose regimen of cefepime, administered over a 30 min infusion, against usual dosage regimens in the treatment of patients with normal renal function with GNB bloodstream infections (BSIs).
Patients and methods

Study design, setting and participants
This was a single-centre prospective cohort study performed at Hospital de Clínicas de Porto Alegre, an 845 bed tertiary care teaching hospital in Porto Alegre, Brazil. All episodes of GNB BSI in patients aged ≥18 years between 1 April 2011 and 28 February 2013 were eligible for the cohort. GNB BSIs were detected through daily review of blood culture results. Patients were included if they received therapy with cefepime within the first 72 h of blood culture collection. They were excluded if they died or were discharged within the first 48 h after blood culture collection, if they presented a baseline creatinine .1.5 mg/dL or if they received cefepime for ,48 h. Only the first episode was analysed if patients had .1 BSI treated with cefepime. Therapy, including dosage regimen and management of the patients, was at the discretion of the attendant physician, who was unaware of the cefepime MIC (performed only a posteriori for this research) but based treatment on a disc diffusion susceptibility result. The study was approved by the local ethics committee, which waived the need to obtain informed consent.
Variables and definitions
The outcome was hospital mortality defined as death due to any cause during hospitalization. A high-dose cefepime regimen was defined as 2 g every 8 h administered over a 30 min infusion. Other dosage regimens were named 'usual'. Covariables potentially associated with mortality were assessed, including: age; gender; Charlson comorbidity score; 13 length of hospital stay before BSI; intensive care unit (ICU) hospitalization at the time of BSI; baseline creatinine level; previous antibiotics use (for ≥48 h) in the last 14 days before BSI; bacterial species; hospital onset of BSI (defined as BSI occurring ≥48 h after hospitalization); low-risk primary site-defined as urinary tract or central venous catheter infections (site of infection was defined according to CDC criteria; 14 central venous catheter infection was also considered the primary site if the differential positivity time of blood culture drawn simultaneously from central venous catheter and peripheral sites was ≥2 h); polymicrobial infection (isolation of .1 organism from blood, excluding coagulase-negative staphylococci in a single blood culture); presentation of BSI with severe sepsis or septic shock; 15 time to initiation of cefepime (≤24, .24 and ≤48, or .48 and ≤72 h); change of antibiotic during the first 14 days after initiation of cefepime; and combination therapy.
Microbiology
All isolates were identified by the VITEK system (bioMérieux, Marcy-l'Étoile, France). Susceptibility was determined using the disc diffusion method and the results were interpreted according to CLSI criteria. 16 Cefepime MICs were determined using the Etest (bioMérieux).
Statistical analysis
All statistical analyses were carried out using SPSS for Windows, version 18.0. Bivariate analysis was performed separately for each of the variables. P values were calculated using the x 2 or Fisher's exact test for categorical variables and the Student's t-test or the Wilcoxon rank-sum test for continuous variables.
Covariates were first compared between high-and usual-dose regimens. Those with a P value ≤0.20 were included in a logistic regression model performed to create a propensity score for high-dose therapy. A bivariate analysis of factors associated with mortality was performed. Variables with a P value ≤0.20 were included in a Cox proportional hazards model, using a forward stepwise regression, along with the propensity score. Variables were checked for confounding and collinearity. A P value ≤0.10 was maintained in the model. Dose regimen and cefepime MIC were maintained in the model regardless of the P value. Proportional hazards assumption was graphically checked by inspecting the log[2log(S)] plot. Tests for interactions were not performed. All tests were two-tailed and P≤0.05 was considered significant.
Results
A total of 689 GNB isolates were recovered from the blood cultures of adult patients during the study period. Of these, 166 received cefepime therapy within 72 h of blood collection; 48 were excluded because they died (n¼ 28) or were discharged (n ¼ 20) within 48 h and five had baseline creatinine .1.5 mg/dL, resulting in a total of 113 patients included for analysis ( Figure 1 ).
BSIs were most commonly caused by Escherichia coli (62, 54.9%), followed by Pseudomonas aeruginosa (19, 16.8%); Klebsiella pneumoniae (15, 13.3%); Serratia marcescens (8, 7.1%); Enterobacter spp. (3, 2.7%); Acinetobacter baumannii (3, 2.7%); Klebsiella oxytoca (2, 1.8%) and Proteus penneri (1, 0.9%). Cefepime MICs ranged from 0.0312 to 16 mg/L; the median MIC was 0.0625 mg/L (IQR 0.312 -0.125). The modal MIC was 0.0625 mg/L and most (78.8%) MICs were ≤0.25 mg/L. There was only one extended-spectrum b-lactamase-producing K. pneumoniae isolate and no isolate was resistant to carbapenems.
High-dose cefepime was administered in 39 (34.5%) patients, while the remaining 74 (65.5%) received usual doses: 2 g every 12 h (42, 56.8%), 1 g every 8 h (5, 6.8%) and 1 g every 12 h (27, 36.5%). There was no difference in mortality among these three usual-dose regimens (P ¼ 0.61). Fifty-one (45.1%) patients changed their therapy during the first 14 days of treatment: 27 (52.9%) modified therapy to a narrower spectrum drug and 24 (47.1%) changed therapy to a similar (piperacillin/tazobactam, n ¼ 11) or a broader spectrum antibiotic (meropenem, n ¼ 12; polymyxin B, n¼ 1). Among the 13 patients who received broader spectrum antibiotics, 6 were from the high-dose group and 7 from the usual-dose groups. There was no significant difference in treatment change proportion among patients receiving high and usual doses of cefepime (41.0% and 47.3%, respectively; P ¼ 0.66). There was also no significant difference in modifications to narrower and broader spectrum antibiotics between patients receiving high and usual doses, respectively (P ¼ 0.58). The mean+SD duration of cefepime among patients who changed therapy was 4.0+2.4; 4.4+3.5 and 3.8+1.6 days in patients receiving high-and usual-dose regimens, respectively (P ¼ 0.49). The mean+SD duration of cefepime treatment was 7.5+3.3 days in survivor patients who did not change therapy; 7.9+3.1 and 7.1+3.6 days in patients receiving high-and usualdose regimens, respectively (P ¼ 0.46). Patients were hospitalized in clinical (71, 62.8%), surgical (15, 13.3%) and emergency (15, 13.3%) wards or ICUs (12, 10.6%) when cefepime was prescribed and there was no difference among these units between highand usual-dose regimens (P ¼0.69).
The overall hospital mortality was 35.4% (40/113); 25.6% (10/ 39) and 40.5% (30/74) in patients receiving high-and usual-dose regimens, respectively [relative risk (RR) 0.63; 95% CI 0.35-1.15; P ¼ 0.17]. The mortality rate was 12.1 and 26.0 per 1000 patientdays among patients treated with high and usual doses (log-rank test: P¼ 0.03). Crude hospital mortality and mortality rates in distinct groups are shown in Table 1 Six (15.4%) and 15 (20.3%) patients receiving high and usual doses, respectively, presented with a BSI caused by GNB with a cefepime MIC .1 mg/L (P ¼ 0.70). One (2.6%) and five (6.8%) patients receiving high and usual doses, respectively, presented with a BSI caused by GNB with a cefepime MIC ≥8 mg/L (P¼ 0.32).
The distribution of variables between the high-and usual-dose groups is displayed in Table 2 . Hospital-acquired BSI, length of hospital stay before BSI, low-risk primary site, age and baseline creatinine levels were the variables selected for creating the propensity score (Hosmer -Lemeshow test, P ¼ 0.78).
The results of the bivariate analysis of factors associated with hospital mortality are shown in Table 3 . Treatment with high-dose cefepime, Charlson score, presentation with severe sepsis or septic shock, cefepime MIC and propensity score were included in the Cox regression model. High-dose cefepime was independently associated with lower mortality rates, while presentation with severe sepsis or septic shock was independently associated with higher mortality rates ( Table 4 ). The results of the multivariate model and the subgroup models are presented in Table 4 . Adjusted survival curves according to cefepime dose regimen are shown in Figure 3 .
Discussion
Our study showed that treatment with cefepime at a dose of 2 g every 8 h over a 30 min infusion was associated with significantly lower hospital mortality rates in patients with GNB BSI when compared with more usual dosage regimens such as 1 g or 2 g every 12 h and 1 g every 8 h. Notably, these results were observed in a population with BSI caused by GNB with low MICs of cefepime, mostly ≤0.25 mg/L. 
Cefepime dose and mortality
It is interesting that Monte Carlo simulation studies have shown that in patients with normal renal function, cefepime doses of 1 g or 2 g every 12 h administered over 0.5 h present a PTA .90% for a PK/PD target of fT .MIC ¼ 50% -60%) when the MIC is 1.0 mg/L. 10, 17 By contrast, for a target of fT .MIC ¼ 65%, a PTA .90% is only found with an MIC ≤0.5 mg/L for a dose of 2 g every 12 h and with an MIC ≤0.25 mg/L for a dose of 1 g every 12 h, 9 although it may slightly vary depending on the population evaluated. 18 -21 Thus, considering that the PTA of a PK/PD target of fT .MIC ¼60% is relatively similar for these distinct dosage regimens when the MIC of the infecting organism is ≤1 mg/L, our results allow us to speculate that the optimal PK/PD target of cefepime may be fT .MIC .60% or that a concentration sustained above the MIC may also be relevant for bactericidal activity, as demonstrated in a previous study, when a concentration of 4×MIC was associated with better microbiological outcomes.
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A significant association between concentration/MIC and microbiological outcome has also been found in another study. 17 This might explain why higher dose regimens were associated with better clinical outcomes even for GNB with very low MICs. A possible role for concentration above the MIC as an important determinant of cefepime efficacy is also supported in our study by the fact that even very low differences in MICs were significantly associated with mortality.
Of note, cefepime MICs were higher in patients who died, despite the fact that they could be considered very low. Although not statistically significant in the multivariate model, we defined a priori that this variable should be maintained in the model, regardless of its P value, to evaluate MIC and dose regimen in the same model.
Although we did not assess creatinine clearance, we analysed a highly homogeneous population regarding creatinine levels. This was done in order to avoid a potential misclassification of dosage regimens 'adjusted' for renal function. Moreover, as with other b-lactams, cefepime clearance is highly associated with creatinine clearance, 19 and this might be a potential cause for distinct outcomes. In fact, only 10 (8.8%) patients had creatinine levels between 1.3 and 1.5 mg/dL (theoretically more likely to have lower creatinine clearances), six of them (five survivors and one non-survivor) in the usual-dose group. The latter could potentially be exposed to isometric plasma concentrations of cefepime as the high-dose group patients. However, it would only favour the null hypothesis; thus, we believe that such a potential bias, if it occurred (considering the low number of patients with creatinine levels closer to 1.5), has not affected our results.
Our study was limited because we did not evaluate secondary outcomes such as microbiological and clinical cure. Indeed, this evaluation was not performed owing to the lack of robust criteria for these outcomes. So, we preferred to assess only hard outcomes such as mortality. Another potential limitation is that the primary outcome was analysed in an intention-to-treat population, since some patients switched from cefepime to another drug during the first 14 days of therapy. However, we are convinced that it has not affected our results because treatment modifications were neither associated with the outcome nor with the variable in study, i.e. cefepime dose. Additionally, this intention-to-treat population may more likely represent the reallife setting, and furthermore, the results in the subgroups of patients who changed and did not change therapy, although not statistically significant (probably owing to the lower number of patients) pointed toward the same direction as the results of the entire cohort. Also of note, either crude hospital mortality or mortality rate tended to be higher in usual-dose than high-dose regimens in distinct subgroups of patients, with the exception of patients who changed therapy to a narrow-spectrum antibiotic. However, the low number of patients who died in this subgroup complicates the interpretation of this latter finding. In summary, cefepime at a dose of 2 g every 8 h administered over a 30 min infusion was associated with lower mortality rates in patients with normal renal function who had GNB BSIs, predominantly with very low cefepime MICs. This finding may at least partially explain the increased mortality rates observed with cefepime therapy when compared with other drugs in clinical trials in which these high doses were very uncommonly administered. The reasons why high-dose regimens may affect the survival of patients with GNB even with low cefepime MICs must be further investigated in clinical studies involving PK/PD analysis.
